Levonordefrin

CHEMBL677 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
183.2 g/mol
LogP
-0.8
Phase
4

Dental local anaesthesia is the setting for levonordefrin, a sympathomimetic vasoconstrictor formulated together with a local anaesthetic rather than used alone. Constricting vessels at the injection site slows systemic absorption of the anaesthetic, which both prolongs the block and reduces bleeding in the operative field. The vasoconstrictor contributes nothing to nerve conduction blockade itself; that effect belongs to the anaesthetic component, and the two act on entirely separate targets. Retaining the anaesthetic locally also limits the plasma concentration it attains. The molecule is small, C9H13NO3 at roughly 183.2 g/mol, and is an approved agent whose development reached the final clinical phase.

A sympathomimetic vasoconstrictor used in combination with local anesthetics in dental procedures to prolong anesthesia and reduce bleeding. It narrows blood vessels at the injection site to slow the absorption of the anesthetic.

Khối lượng phân tử

183,2000 g/mol

LogP

-0,80

TPSA

86,70 Ų

Lipinski RO5

Đạt

Lĩnh vực điều trị

Cơ chế tác dụng

A sympathomimetic amine acting as an alpha-adrenergic receptor agonist. Levonordefrin constricts arterioles at the injection site, slowing systemic uptake of the local anaesthetic it is formulated with. The anaesthetic, not levonordefrin, blocks voltage-gated sodium channels; the vasoconstriction prolongs that block and reduces bleeding in the surgical field.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

A sympathomimetic amine acting as an alpha-adrenergic receptor agonist. Levonordefrin constricts arterioles at the injection site, slowing systemic uptake of the local anaesthetic it is formulated with. The anaesthetic, not …

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@H](N)[C@H](O)c1ccc(O)c(O)c1

InChI

InChI=1S/C9H13NO3/c1-5(10)9(13)6-2-3-7(11)8(12)4-6/h2-5,9,11-13H,10H2,1H3/t5-,9-/m0/s1

Molecular Formula

C9H13NO3

HBD / HBA

4 / 4

Liên kết có thể quay

2

Nguyên tử nặng

13

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A sympathomimetic vasoconstrictor used in combination with local anesthetics in dental procedures to prolong anesthesia and reduce bleeding. It narrows blood vessels at the injection site to slow the absorption of the anesthetic.

A sympathomimetic amine acting as an alpha-adrenergic receptor agonist. Levonordefrin constricts arterioles at the injection site, slowing systemic uptake of the local anaesthetic it is formulated with. The anaesthetic, not levonordefrin, blocks voltage-gated sodium channels; the vasoconstriction prolongs that block and reduces bleeding in the surgical field.

Yes, Levonordefrin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL677. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 164739. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.